The SMuRFless Coronary Artery Disease (CAD) Registry: An observational study of the quality of care and risk factors in patients with CAD but without Standard Modifiable cardiovascular Risk Factors (SMuRFs)

Not Applicable

Recruiting

• Conditions: Cardiovascular disease; Cardiovascular - Coronary heart disease

• Registration Number: ACTRN12622000452796
• Lead Sponsor: The University of Sydney

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2022-03-23
• Last Update Posted: 22 July 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 1000

Inclusion Criteria

•18 years of age or older
•A clinically indicated visit to an NHMRC CRE for CAD clinic
•Diagnosed or suspected atherosclerotic coronary artery disease (CAD), based on invasive coronary angiography or CT coronary angiography findings, or a family member of an individual with diagnosed CAD
•Willing and able to provide informed consent by self

Exclusion Criteria

•Prior medical diagnosis of hypertension
•Prior medical diagnosis of hyperlipidaemia
•Prior medical diagnosis of diabetes mellitus
•History of tobacco smoking within the past 12 months
•Patients highly dependent on medical care and unable to provide informed consent
•People with cognitive impairment, intellectual disability, or mental illness that prevent them from providing informed consent for themselves

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To measure utilisation of the NHMRC Centre for Research Excellence in CAD clinical pathway by pathway tests completed for the participant in the clinic setting.[ Assessed at the time of enrolment for up to 5-years];To measure results of tests included in the NHMRC Centre for Research Excellence in CAD clinical pathway[ Assessed at the time of enrolment]

Secondary Outcome Measures

Name	Time	Method
Cost effectiveness of the NHMRC CRE clinical pathway in identifying risk factors of CAD progression by Medicare Benefits Schedule (MBS) / Pharmaceutical Benefits Scheme (PBS) data linkage.[ Assessed at the time of enrolment and 5 years post-enrolment];Rate of major adverse cardiovascular events (MACE) utilising MBS data linkage[ 5 years post-enrolment]